Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€27.05

€27.05

0.190%
0.05
0.190%
-
 
08:14 / Tradegate WKN: STRA55 / Name: Stratec / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Your prediction

Stratec SE Stock

The Stratec SE stock is trending slightly upwards today, with an increase of €0.050 (0.190%) compared to yesterday's price.
For the coming years our community has positive and negative things to say abot the Stratec SE stock. Criterium "Unique positioning" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Stratec SE in the next few years

Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Stratec SE vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Stratec SE 0.190% 1.124% 10.204% -43.277% -9.850% -73.684% -67.153%
Paul Hartmann AG 0.400% 2.033% -0.791% 23.645% 12.556% -20.317% -22.050%
Eckert & Ziegler Strahlen- und Medizintechnik AG -0.240% 2.331% 5.907% 38.671% 43.227% 52.127% 74.384%
Geratherm Medical AG -1.930% -2.508% 8.741% -23.775% -10.632% -62.976% -69.510%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2024-08-01

The financials of Stratec, a company operating in the Healthcare Equipment & Supplies industry, present a mixed picture. On one hand, the firm exhibits solid revenue generation capabilities and figures that suggest a growing market presence. On the other hand, certain financial metrics raise concerns about its profit margins and growth potential. A careful examination of the balance sheet, cash flow statements, income statements, and financial ratios reveals both strengths and weaknesses.

*Pros: *

Strong Revenue Generation: Stratec reported a total revenue of €261.91 million in 2023, with a consistent upward trend observed over the previous years. This reflects the company’s capacity to capture market share and expand its operations in a growing healthcare sector.

Comments

systinvest bought the security Stratec SE in his wikifolio Aktienwertselektion mit System.
Show more

Prediction Buy
Perf. (%) 30.79%
Target price 53.240
Change
Ends at 08.04.19

(Laufzeit überschritten)
Show more

Prediction Buy
Perf. (%) 30.79%
Target price 53.240
Change
Ends at 08.04.19

(Laufzeit überschritten)
Show more

News

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2025
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR
EQS-News: STRATEC REPORTS RESULTS FOR 2024 FINANCIAL YEAR
EQS-Adhoc: STRATEC REPORTS PRELIMINARY BUSINESS RESULTS FOR 2024, PROVIDES GUIDANCE FOR 2025, AND POSTPONES 2024 ANNUAL REPORT
EQS-Adhoc: STRATEC REPORTS PRELIMINARY BUSINESS RESULTS FOR 2024, PROVIDES GUIDANCE FOR 2025, AND POSTPONES 2024 ANNUAL REPORT
EQS-Adhoc: STRATEC REPORTS PRELIMINARY BUSINESS RESULTS FOR 2024, PROVIDES GUIDANCE FOR 2025, AND POSTPONES 2024 ANNUAL REPORT